LC
DNA icon

Lindbrook Capital’s Ginkgo Bioworks DNA Stock Holding History

Lindbrook Capital’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$393 Buy
69
+44
+176% +$448 ﹤0.01% 2661
2024
Q4 		$246 Hold
25
– – ﹤0.01% 2702
2024
Q3 		$204 Hold
25
– – ﹤0.01% 2769
2024
Q2 		$334 Sell
25
-27
-52% -$806 ﹤0.01% 2677
2024
Q1 		$2.39K Sell
52
-147
-74% -$7.61K ﹤0.01% 2177
2023
Q4 		$13.4K Sell
199
-4
-2% -$245 ﹤0.01% 1382
2023
Q3 		$14.7K Sell
203
-85
-30% -$6.8K ﹤0.01% 1210
2023
Q2 		$21.4K Buy
288
+109
+61% +$6.45K ﹤0.01% 1055
2023
Q1 		$9.51K Buy
179
+172
+2,457% +$10.9K ﹤0.01% 1485
2022
Q4 		$502 Buy
7
+5
+250% +$460 ﹤0.01% 2600
2022
Q3 		$0 Buy
+2
New +$238 ﹤0.01% 2680

Other funds holding DNA

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Lindbrook Capital's DNA Position: Q1 2025 in Review

Lindbrook Capital increased its Ginkgo Bioworks (DNA) stake by 176% in Q1 2025, buying an estimated $448 and bringing the position to 69 shares worth $393. The position accounts for ﹤0.01% of the portfolio, ranked #2661.

Lindbrook Capital first reported a position in DNA in Q3 2022 and has held it in 11 quarters since. The position peaked at $21.4K in Q2 2023. 166 funds tracked by Wall St. Rank hold DNA as of Q1 2025.

  • Lindbrook Capital held 69 shares of Ginkgo Bioworks worth $393 as of Q1 2025.
  • Lindbrook Capital bought 44 Ginkgo Bioworks shares in Q1 2025, an estimated $448.
  • Ginkgo Bioworks made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2661 holding.
  • Lindbrook Capital first reported a position in Ginkgo Bioworks in Q3 2022 and has held it in 11 quarters since.
  • Lindbrook Capital's Ginkgo Bioworks position peaked at $21.4K in Q2 2023.
  • 166 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.